Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout
Authors' conclusion
People with combined subtype have a lower response to febuxostat, compared to those with either overload or underexcretion subtype.
Study context
- Population
- Gout patients with the three major clinical subtypes of hyperuricemia treated with febuxostat (20 mg daily, escalating to 40 mg daily if not at target) for 12 weeks
- Participants
- 644 patients
- Exposure
- Febuxostat response by hyperuricaemia subtype: combined vs renal overload vs renal underexcretion
- Outcome
- Rate of achieving SU < 6 mg/dL
- Follow-up
- Week 12
Main finding
As reported in the abstract
Achieving SU < 6 mg/dL
Combined subtype vs Overload subtype: P = 0.007 · Combined subtype vs Underexcretion subtype: P = 0.022
Observational data: associations, not effects.
Further findings
Febuxostat escalated to 40 mg — Combined subtype vs Overload subtype
P = 0.001
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Factors independently associated with achieving SU target (all participants)Combined subtypevs Overload subtypeCombined subtype hyperuricemia | 0.64 (0.41–0.99) | P = 0.048 | |
| 0.512Odds ratio (log scale) |
Factors independently associated with achieving serum urate (SU) target (all participants)
| OR (95% CI) | P value | ||
|---|---|---|---|
| Baseline SU | 0.74 (0.62–0.89) | P = 0.001 | |
| 0.512Odds ratio (log scale) |
| Outcome | P value |
|---|---|
| Febuxostat escalated to 40 mgCombined subtype vs Underexcretion subtype | P = 0.001 |
Original publication
Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout. Arthritis Res Ther. Published 11 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →